Individualized antisecretory and polyenzyme therapy of mild acute pancreatitis

The article is devoted to the study and elaboration of principles of differentiated antisecretory and multienzyme therapy of acute edematous pancreatitis. The aim: to evaluate the effectiveness of high doses of multienzyme preparations for the treatment of acute edematous pancreatitis in comparison with the main antisecretory drugs and to determine the main indications for the differentiated application. Material and methods. This article uses the results of treatment of 165 patients with acute mild pancreatitis of different etiology using only basic therapy (11 patients - 6.7%), various antisecretory drugs (91 patients - 55.2%) and multienzyme preparation, Ermytal 36 000 (63 patients - 38.2%). Verification of diagnosis was carried out based on the typical complaints and medical history, ultrasound, fibrogastroduodenoscopy and laboratory research. Results. A review of the literature on the mechanisms of negative feedback is allowed to justify the use of high doses multienzyme drugs to suppress the release of pancreatic enzymes and functional rest the pancreas during acute edematous pancreatitis. Based on the statistical analysis assessed the impact of antisecretory and multienzyme preparations on dynamics of the main pathophysiologic changes in patients with acute pancreatitis mild. Own data have confirmed the efficacy of the drug, Ermytal 36 000. Based on this, the principles of differentiated antisecretory therapy and worked out indications for use of high doses of multienzyme preparations in the treatment of acute pancreatitis are mild. Differentiated antisecretory therapy and the use of multienzyme preparations allowed us on the background of the annual growth of total incidence of acute pancreatitis is to decrease the frequency of readmissions from 10.5% to 1.6%.

acute pancreatitis mild antisecretory therapy, multienzyme preparations